The Tremulous Admission
A 41-year-old man with a 12-year history of daily alcohol use (approximately 1 pint of vodka plus 6 beers per day, last drink 14 hours ago) is brought to the emergency department by his brother. Vital signs: HR 118, BP 162/98, temperature 37.4 C, respirations 20, SpO2 96% on room air. He is alert but tremulous, diaphoretic, and reports 'bugs on the wall.' He scores 14 on the CIWA-Ar. Labs: sodium 134, potassium 3.2, magnesium 1.4, glucose 96, AST 88, ALT 62, platelets 98, INR 1.3. He has no history of seizures but his brother reports a prior 'bad withdrawal' episode 3 years ago that required hospitalization. He denies suicidal ideation and has no other intoxicants on urine screen.
1. Identify the immediate risk stratification and the first-line pharmacologic plan, including agent, route, and monitoring parameters.
Read the worked answer
Risk stratification: This is complicated withdrawal with features that place him at elevated risk for progression. Key drivers: CIWA-Ar of 14, autonomic hyperactivity (HR 118, BP 162/98), visual hallucinations (a marker of alcohol withdrawal hallucinosis, which can herald delirium tremens), electrolyte derangement (hypokalemia, hypomagnesemia), thrombocytopenia, and a prior severe withdrawal episode - the single strongest historical predictor of complicated withdrawal. He is not yet delirious (alert, oriented) but is on the trajectory.
Pharmacology:
- Benzodiazepine-based symptom-triggered therapy is first-line. Diazepam 10 mg IV or lorazepam 2 mg IV depending on hepatic function; given his elevated transaminases and thrombocytopenia, lorazepam (glucuronidated, less hepatic-dependent) is often favored, though diazepam's longer half-life smooths the course. Either is defensible if justified.
- Thiamine 100 mg IV before or with glucose-containing fluids to prevent Wernicke encephalopathy.
- Electrolyte repletion: potassium and magnesium; hypomagnesemia perpetuates hypokalemia and lowers seizure threshold.
- Do not use antipsychotics as monotherapy (lowers seizure threshold, masks worsening), and avoid relying on them for the hallucinations - treat the underlying withdrawal.
Monitoring: CIWA-Ar reassessment frequently (e.g., hourly during active treatment), continuous pulse oximetry, telemetry, serial vitals, and a low threshold to escalate to a monitored/ICU-level setting if he develops disorientation, fever, or refractory autonomic instability. Hallucinations without delirium do not mandate ICU, but the trajectory does.
2. The patient asks why he cannot simply be given a 'taper pill' and go home. How do you justify the level-of-care decision using withdrawal risk and his social situation?
Read the worked answer
Justification framework: Level of care should match the intensity of expected withdrawal and the safety of the environment.
- Withdrawal severity trajectory: His CIWA of 14 with hallucinations and prior complicated withdrawal means his symptoms are likely to worsen over the next 24–72 hours, not improve. Alcohol withdrawal peaks later than many patients expect, and a home taper assumes a stable, monitored course.
- Medical comorbidity: Electrolyte abnormalities, thrombocytopenia, and transaminitis require correction and monitoring that home cannot provide; hypomagnesemia and hypokalemia increase arrhythmia and seizure risk.
- Safety: Hallucinations impair judgment; a home environment without 24-hour observation cannot detect progression to delirium tremens, which carries significant mortality if untreated.
- Ethical/clinical communication: Explain that the taper is not a substitute for monitoring - it is a component of a monitored plan. Offer a residential or inpatient withdrawal management stay with a structured benzodiazepine taper, then transition to ongoing treatment. Frame it as protecting him during the highest-risk window rather than as punishment or loss of autonomy.